Proposed Changes to Contamination Limits

The Union Health Ministry has announced plans to tighten contamination limits for the cleanest zones in sterile drug manufacturing facilities. This proposal was made public on 28 October, just two days prior to regulators instructing Sun Pharma to cease production of eye-care medications at its Assam facility. The changes aim to align Indian regulations with those set by the World Health Organisation (WHO), specifically regarding the acceptable levels of microbial presence in Grade A areas, which are critical zones where exposed products and sterilised components are handled.

The amendment stipulates that any detection of microbial growth in these vital areas must initiate a thorough investigation. This step is significant in ensuring the safety and efficacy of sterile products, particularly in light of recent contamination issues faced by major manufacturers.

Background of Sun Pharma’s Contamination Issues

This regulatory development follows a serious incident involving Sun Pharma, India’s largest pharmaceutical company, which was ordered to halt production at its Assam plant due to reported contamination in some of its eye drop products. On 19 June, the All India Ophthalmological Society (AIOS) alerted its members about potential contamination in batches of Sun’s Predmet eye drops, which are steroid-based and used to treat inflammation in the eyes. The contamination was identified as being consistent with Pseudomonas bacteria, known to be opportunistic pathogens in humans.

In response to these findings, Sun Pharma initially withdrew the Predmet eye drops and subsequently expanded its recall to include 11 ophthalmic products on 17 July. Following this, regulators issued a show-cause notice on 10 August, citing deficiencies in the company’s quality management system. Most recently, production at the Assam facility was halted after the recall of 332 batches of ophthalmic products.

The regulatory scrutiny reflects a growing concern over the quality control measures in place at Sun Pharma, particularly in its sterile manufacturing processes. Experts have highlighted that any lapses in sterility can have direct implications for patients, especially those using eye drops prescribed after surgery or for conditions such as glaucoma and infections.

Implications of the Regulatory Changes

India’s existing Schedule M contamination limits for Grade A areas differ from those established by the WHO, and the recent amendment seeks to eliminate this discrepancy. For manufacturers, the most notable change is the requirement for an investigation following any positive microbial test result in these critical clean areas. This shift underscores the importance of stringent sterility protocols in the production of sterile medications.

A senior member of the AIOS emphasised that maintaining sterility during the manufacturing process is essential, particularly in a country where millions rely on eye drops daily. Although ophthalmology contributes only about 3 per cent to Sun Pharma’s domestic revenue, the implications of regulatory actions extend beyond this segment, affecting the company’s overall reputation and operational practices.

In a related context, the US Food and Drug Administration (FDA) had previously halted shipments from Sun Pharma’s Halol plant in Gujarat due to identified shortcomings in contamination controls. This marks the second instance within two years that the company has faced regulatory challenges concerning its sterile manufacturing practices. As of now, there has been no confirmation regarding any adverse effects reported by patients who may have used the contaminated eye drops.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store – https://apps.apple.com/in/app/newspin/id6746449540

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share